Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001341870 | SCV001535765 | uncertain significance | Renal cell carcinoma | 2021-04-16 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with MET-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces aspartic acid with glutamic acid at codon 1057 of the MET protein (p.Asp1057Glu). The aspartic acid residue is moderately conserved and there is a small physicochemical difference between aspartic acid and glutamic acid. |
| Ambry Genetics | RCV002322282 | SCV002610045 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-08-02 | criteria provided, single submitter | clinical testing | The p.D1057E variant (also known as c.3171C>G), located in coding exon 14 of the MET gene, results from a C to G substitution at nucleotide position 3171. The aspartic acid at codon 1057 is replaced by glutamic acid, an amino acid with highly similar properties. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |